Science· 2015Q1
Neoantigens in cancer immunotherapy
- 4,785citations
- Q1SCImago
- 2015year
Short summary
Recognition of patient-specific neoantigens, arising from tumor mutations, is a key driver of clinical cancer immunotherapy efficacy.
AI-generated from the title and abstract; the full text is not read.
Key points
- T cell control of human cancers is clinically established.
- Neoantigens, arising from tumor-specific mutations, distinguish cancer from normal cells.
- Recognition of neoantigens is a major factor in clinical immunotherapy activity.
- Neoantigen load may become a biomarker for cancer immunotherapy.
AI-generated from the title and abstract; the full text is not read.
Abstract
The clinical relevance of T cells in the control of a diverse set of human cancers is now beyond doubt. However, the nature of the antigens that allow the immune system to distinguish cancer cells from noncancer cells has long remained obscure. Recent technological innovations have made it possible to dissect the immune response to patient-specific neoantigens that arise as a consequence of tumor-specific mutations, and emerging data suggest that recognition of such neoantigens is a major factor in the activity of clinical immunotherapies. These observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.
The authors' abstract, as published at the source. Science, 2015 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Oncology
OncologyMedicine